Who owns AN2 THERAPEUTICS INC?
- Ticker: ANTX
- CUSIP Number: 037326105
Tip: Access positions for across all investors
Analyze quarterly positions in An2 Therapeutics with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of An2 Therapeutics stock
Who bought or sold AN2 THERAPEUTICS INC this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| BML Capital Management | 5.7M | $7.9M | 0% | Dec 2024 |
|
| Almitas Capital | 1.3M | $1.8M | 100% | Dec 2024 |
|
| Vanguard Group | 1.0M | $1.4M | -1% | Dec 2024 |
|
| Renaissance Technologies | 580k | $800k | 37% | Dec 2024 |
|
| Peapod Lane Capital | 579k | $799k | 100% | Dec 2024 |
|
| Two Sigma Advisers | 528k | $729k | 337% | Dec 2024 |
|
| Bank Of Montreal | 422k | $583k | 100% | Dec 2024 |
|
| Two Sigma Investments | 400k | $553k | 125% | Dec 2024 |
|
| Bank of Nova Scotia | 395k | $545k | 100% | Dec 2024 |
|
| Bank of America Corporation | 386k | $532k | 2278% | Dec 2024 |
|
| Aldebaran Capital | 344k | $474k | 242% | Dec 2024 |
|
| Adage Capital Partners GP | 313k | $431k | 0% | Dec 2024 |
|
| BlackRock | 301k | $416k | 0% | Dec 2024 |
|
| Geode Capital Management | 228k | $314k | 3% | Dec 2024 |
|
| Millennium Management | 209k | $289k | -47% | Dec 2024 |
|
| Stonepine Capital Management | 197k | $272k | 100% | Dec 2024 |
|
| UBS Group | 170k | $235k | 100% | Dec 2024 |
|
| Bridgeway Capital Management | 162k | $224k | -18% | Dec 2024 |
|
| State Street Corporation | 87k | $120k | 44% | Dec 2024 |
|
| Marquette Asset Management | 83k | $115k | 29% | Dec 2024 |
|
| Citadel Advisors | 68k | $94k | 100% | Dec 2024 |
|
| Squarepoint Ops | 62k | $86k | 100% | Dec 2024 |
|
| Northern Trust | 43k | $60k | 33% | Dec 2024 |
|
| XTX Topco | 34k | $47k | 44% | Dec 2024 |
|
| Captrust Financial Advisors | 29k | $40k | 0% | Dec 2024 |
|
| Schonfeld Strategic Advisors | 27k | $37k | -59% | Dec 2024 |
|
| Integrated Wealth Concepts | 25k | $35k | 0% | Dec 2024 |
|
| Private Advisor | 23k | $31k | 0% | Dec 2024 |
|
| Qube Research & Technologies | 10k | $14k | 100% | Dec 2024 |
|
| Federated Investors | 7.5k | $10k | 149% | Dec 2024 |
|
| Tower Research Capital | 1.5k | $2.0k | -66% | Dec 2024 |
|
| Bnp Paribas Arbitrage, Snc | 312.00 | $430.996800 | 100% | Dec 2024 |
|
| Advisor Group Holdings | 300.00 | $321.000000 | 0% | Dec 2024 |
|
| Morgan Stanley | 300.00 | $414.000000 | -1% | Dec 2024 |
|
| SBI Securities | 200.00 | $276.000000 | 100% | Dec 2024 |
|
| Jpmorgan Chase & Co | 52.00 | $71.999200 | -4% | Dec 2024 |
|
Who sold out of An2 Therapeutics?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| RA Capital Management | Sep 2024 | 2.0M | $2.1M |
| TCG Crossover Management | Sep 2024 | 1.6M | $1.7M |
| Acuitas Investments | Sep 2024 | 446k | $477k |
| Ghost Tree Capital | Jun 2024 | 219k | $472k |
| Jacobs Levy Equity Management | Sep 2024 | 79k | $85k |
| Acadian Asset Management | Sep 2024 | 42k | $45k |
| Occudo Quantitative Strategies | Jun 2024 | 35k | $76k |
| FMR | Sep 2024 | 300.00 | $321.000000 |